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Abstract
Objectives: To develop a population specific pharmacogenetic acenocoumarol dosing algorithm for north Indian patients
and show its efficiency in dosage prediction.
Methods: Multiple and linear stepwise regression analyses were used to include age, sex, height, weight, body surface area,
smoking status, VKORC1 -1639 G.A, CYP4F2 1347 G.A, CYP2C9*2,*3 and GGCX 12970 C.G polymorphisms as variables to
generate dosing algorithms. The new dosing models were compared with already reported algorithms and also with the
clinical data for various performance measures. Odds ratios for association of genotypes with drug sensitive and resistant
groups were calculated.
Results: The pharmacogenetic dosing algorithm generated by multiple regression analysis explains 41.4% (p-value ,0.001)
of dosage variation. Validation of the new algorithm showed its predictive ability to be better than the already established
algorithms based on similar variables. Its validity in our population is reflected by increased sensitivity, specificity, accuracy
and decreased rates of over- and under- estimation in comparison to clinical data. The VKORC1-1639 G.A polymorphism
was found to be strongly associated with acenocoumarol sensitivity according to recessive model.
Conclusions: We have proposed an efficient north India specific pharmacogenetic acenocoumarol dosing algorithm which
might become a baseline for personalised medicine approach for treatment of patients in future.
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Introduction
The human genome project completion has opened a new era
of pharmacogenetics. Personalized medicine is emerging as a new
therapeutic approach in clinical practice in recent times [1,2].
Coumarinic oral-anticoagulants (COAs) like warfarin, acenocou-
marol and phenprocoumon are the most frequently prescribed
drugs for managing problems associated with blood coagulation in
patients with atrial fibrillation (AF), heart valve replacement
(HVR), deep vein thrombosis (DVT), pulmonary embolism and
with patients who had undergone orthopaedic surgery [3–6].
More than 2 million patients are given warfarin in USA alone for
preventing thromboembolism [7]. In north India, acenocou-
marol/acitrom is widely used in place of warfarin. COA therapy is
generally given lifelong and its dosing management is very difficult
as it has a narrow therapeutic range and there are significant inter-
individual as well as interethnic differences in stabilising dosages.
Lower doses cause decreased efficacy in anticoagulation and
higher doses increase the risk of bleeding events. Therefore, COA
usage requires serial monitoring of blood coagulation by
prothrombin time and international normalized ratio (INR)
measurements. More importantly, the initial phase of COA
therapy is very prone for clinical complications associated with
over or under dosing. Deranged INR values are often observed in
the first weeks of therapy and there is much higher risk of bleeding.
To avoid this risk it is advised to predict the initial loading and
stabilising doses of COAs [8–11]. At present only clinical
parameters are used to predict the drug dose for anticoagulant
therapy. For oral anticoagulants, the dose requirement and inter-
patient variability are well known to be influenced by age, body
weight, dietary vitamin K intake, concomitant disease and
interacting medications [4,12–14]. Genetics is a major role player
in variability of drug dosage requirement to achieve therapeutic
INR range [15–18]. More than 30 genes were found to be
involved in the activity and metabolism of COAs, of which
CYP2C9 (gene coding for cytochrome P450 drug metabolizing
enzyme) and VKORC1 (gene coding for drug target enzyme) are
the most important [19]. Previous studies have shown that ,30%
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phisms (SNPs) in VKORC1 and another ,12% by two non-
synonymous SNPs (*2, *3) in the CYP2C9 region [20,21]. A
genome wide association study has also revealed that VKORC1,
CYP2C9 and CYP4F2 are the principal genetic factors responsible
for variations in COA dose in white patients and the p values are
in concordance with the fact that SNPs in VKORC1 and CYP2C9
regions are most significant [22]. In terms of dose variance,
VKORC1 is found to be more influencing than CYP2C9 in some
recent studies [23,24]. However, the therapeutic drug dosage in an
individual is determined by complex sets of genetic and
environmental factors. Therefore, many attempts have been made
in recent years to develop pharmacogenetics guided dosing
algorithms based on genetic as well as clinical factors
[7,12,17,25]. The algorithm based dose prediction shows the
importance of pharmacogenetic testing in patients who are likely
to undergo COA therapy. Majority of these studies are based on
warfarin dosing and not much has been explored about the
pharmacogenetics of acenocoumarol and phenprocoumon. Perez-
Andreu et al. have shown the importance of pre-genotyping of
VKORC1, CYP4F2, CYP2C9*2 and *3 polymorphisms in patients
requiring extreme doses of acenocoumarol [26]. Recently van
Schie et al. have reported drug specific algorithms for acenocou-
marol and phenprocoumon which are significantly different from
warfarin dosing algorithms [27]. In Indian context, there is no
information available in terms of genetics responsible for
differences in acenocoumarol dosage requirements. Therefore,
we have tried to look up in this direction and attempted to develop
a pharmacogenetic algorithm to predict the stabilizing drug
dosage for a better treatment of Indian patients.
Results
Patient characteristics
Patient characteristics are listed and compared in Table 1
between the derivation and validation cohorts. The minor allele
frequencies of VKORC1-1639 G.A, CYP2C9*2,*3, CYP4F2 1347
G.A, GGCX 12970 C.G polymorphisms in derivation and
validation cohorts were comparable. Table 1 also shows the
distribution of genotypes and corresponding mean acenocoumarol
doses. The VKORC1 -1639 GG, GA and AA genotypes show daily
drug dose requirements of 3.4761.21 mg/kg,2.6060.92 and
1.2560.64 respectively in the derivation cohort. The respective
values for the validation cohort were 3.3961.20 mg/kg,
2.4960.88 mg/kg and 1.4760.22 mg/kg. There was only a
single patient present each in derivation and validation cohorts
with CYP2C9*2*3 genotype and they showed daily maintenance
dosage requirements of 1.28 mg/kg and 2.71 mg/kg respectively.
Comparatively higher drug dose requirements were observed for
CYP2C9*1*1, *1*2 or *1*3 genotypes in both the derivation and
validation cohorts. No significant difference was observed between
patients with different allelic combinations of CYP4F2 1347 G.A
and GGCX 12970 C.G polymorphisms. The trend of dosage
requirement was observed for both the cohorts. All other patient
characteristic were found to be comparable in both the cohorts.
Pharmacogenetic dosing algorithm by multiple
regression
Multiple regression analysis resulted in the following dosing
algorithm: dose (mg/day) =3.082–0.013(smoking status, 1 for
smoker and 0 for non-smoker) –0.433 (gender, 1 for male and 0 for
female) –0.004(age in years) + indication(0.327 for DVR and
20.092 for AVR) +0.026(height in centimetres) +0.151(weight in
kilograms) –7.660(body surface area in cm
2) –0.862(VKORC1
GA) –2.257(VKORC1 AA) –0.049(CYP2C9*2 CT) –
0.456(CYP2C9*3 AC) +0.449(CYP4F2 GA) +0.230(CYP4F2
AA) +0.245(GGCX CG) +1.055(GGCX GG) (Table 2). The
coefficient of determination (R
2) value for this equation is 41.4%
(p-value ,0.001). It means that 41.4% of variation in acenocou-
marol dose is explained by this pharmacogenetic model.
Pharmacogenetic dosing algorithm by linear stepwise
regression
Linear stepwise regression produced a more simple equation
(including the clinical and genetic factors (Table 2). The R
2 value
of this algorithm is 37% (p-value ,0.001), which is the highest
value produced in the stepwise regression modelling for the final
step. This second dosing algorithm was found to have similar
predictive trend as shown by the multiple regression equation.
However, in terms of mean weekly dose and mean absolute error,
the multiple regression equation was more accurate. The values of
mean weekly dose and mean absolute error by stepwise regression
equation were 22.0264.72 (95% CI 21.08–22.96) and 0.7167.86
(95% CI 20.76–2.19).
Performance of new dosing algorithm
When compared with clinical data, the new multiple regression
algorithm showed improvement in various performance measures
like sensitivity (76% vs 51%), specificity (64% vs 49%), rate of
overestimation (22% vs 27%), rate of underestimation (15% vs
23%), overall accuracy (63% vs 50%), accuracy in dug sensitive
cases (60% vs 51%) and accuracy in drug resistant cases (72% vs
49%). The Cronbach’s Alpha constant depicts the relatedness of
dosage data (as a group) predicted by the new algorithm or the
clinical algorithm with the actual therapeutic dosage data. This
value was higher in case of new algorithm in comparison with the
clinical data (0.56 vs 0.11) (Table 3).
Comparision of algorithms
The new multiple regression algorithm predicted better in
comparison to the therapeutic dose in the aspect of standard
deviation from mean weekly dose (Table 4). The mean weekly
dose calculated by this algorithm was 21.2664.82 mg/week (95%
CI 20.30–22.21). This value is closest to that obtained by van
Schie et al. acenocoumarol dosing algorithm, 23.5664.67 mg/
week (95% CI 22.63–24.49) [27]. The values for the algorithms by
Oner Ozgon et al. [28] and Wen et al. [29] were
27.1661.19 mg/week (95% CI 26.92–27.40) and
27.8764.94 mg/week (95% CI 26.89–28.85). The mean value
for therapeutic data of dose was found to be 21.3168.35 mg/week
(95% CI 19.65–22.97) (Table 4). The mean absolute error (MAE)
for the new algorithm was 0.0667.62 mg/week (95% CI 21.57–
1.45). The MAE values were 2.2567.86 (95% CI 0.69–3.81),
5.8467.96 (95% CI 4.26–7.42) and 6.5667.23 (95% CI 5.13–
7.99) for van Schie et al. (acenocoumarol algorithm) [27], Oner
Ozgon et al. [28] and Wen et al. [29] algorithms (Table 4).
Association with acenocoumarol dose
In the study subjects, VKORC1 -1639 G.A polymorphism has
the strongest association with acenocoumarol sensitivity according
to recessive model (OR 4.42, 95% CI 2.44–7.99, p value,0.05).
No other polymorphism was found to be significantly associated
with acenocoumarol sensitive, resistant and intermediate dosing
groups (Table 5).
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Variable Derivation cohort (n=125) Validation cohort (n=100) P value
Heart valve replacement surgery (AVR/MVR/DVR) 26/82/17 18/64/18 0.63
Gender (male/female) 88/37 63/37 0.26
Age (mean 6 SD) 37.45612.27 38.05612.85 0.72
Body weight (kg) (mean 6 SD) 56.08612.16 55.59610.49 0.75
Height (cm) 162.5969.67 162.1968.98 0.75
VKORC1 21639 (GG/GA/AA) 85/34/6 65/32/3 0.62
CYP4F2 1347 (GG/GA/AA) 42/59/24 71/112/42 0.67
CYP2C9 (*1*1/*1*2/*1*3/*2*3) 102/11/11/1 62/10/27/1 0.00
GGCX 12970 (CC/CG/GG) 115/8/2 97/3/0 0.22
INR (mean 6 SD) 2.8160.42 2.8960.44 0.16
Acenocoumarol dose (mg/d) (mean 6 SD)
Overall 3.1361.25 3.0461.19 0.61
VKORC1 -1639 GG 3.4761.21 3.3961.20 0.69
VKORC1 -1639 GA 2.6060.92 2.4960.88 0.61
VKORC1 -1639 AA 1.2560.64 1.4760.22 0.58
CYP4F2 1347 GG 2.8261.07 2.8160.79 0.96
CYP4F2 1347 GA 3.3661.29 3.0161.33 0.16
CYP4F2 1347 AA 3.0861.36 3.5161.23 0.30
CYP2C9*1*1 3.1661.24 3.2861.20 0.53
CYP2C9*1*2 3.0461.39 2.9461.12 0.84
CYP2C9*1*3 3.0861.14 2.5161.09 0.20
CYP2C9*2*3 1.2860.00 2.7160.00 0.38
GGCX 12970 CC 3.1061.27 3.0561.21 0.76
GGCX 12970 CG 3.2560.90 2.9060.70 0.57
GGCX 12970 GG 4.1461.22 - -
AVR/MVR/DVR: Aortic/Mitral/Double Valve Replacement.
doi:10.1371/journal.pone.0037844.t001
Table 2. Algorithm development by multiple and linear stepwise regression analyses.
Method Model, x variables Regression equation P value
R
2 for
model, %
Multiple
regression
VKORC1, CYP4F2, CYP2C9*2, CYP2C9*3,
GGCX Genotypes, weight, height, sex,
age, body surface area, smoking status
and indication for surgery
dose (mg/day) =3.082–0.013 (smoking status, 1 for smoker and 0 for
non-smoker) –0.433 (sex, 1 for male and 0 for female) –0.004(age) +
indication(0.327 for DVR and –0.092 for AVR) +0.026(height) +0.151
(weight) –7.660(body surface area) –0.862(VKORC1 GA) –2.257
(VKORC1 AA) –0.049(CYP2C9*2 CT) –0.456(CYP2C9*3 AC) +0.449
(CYP4F2 GA) +0.230 (CYP4F2 AA) +0.245(GGCX CG) +1.055(GGCX GG)
,0.001 41.4
Linear
stepwise
regression
Weight, Sex adose (mg/day) =1.418+0.038(weight)-0.564 (1 for male, 0 for female) ,0.001 12.5
Linear
stepwise
regression
VKORC1 Genotype, weight dose (mg/day) =0.755+0.896(VKORC1 GG)-
1.396(VKORC1 AA)+0.033(weight)
,0.001 31.0
Linear
stepwise
regression
VKORC1 Genotype, weight, sex dose (mg/day) =0.192+0.879(VKORC1 GG)-1.443(VKORC1 AA)-
+0.04(weight)+0.569(1 for male, 0 for female)
,0.001 34.9
Linear
stepwise
regression
VKORC1, CYP4F2 Genotypes
weight, sex
bdose (mg/day) =2.329(VKORC1 GG) +1.45(VKORC1 GA) +0.362
(CYP4F2 GA) +0.038(weight) –0.535(1 for male, 0 for female) –0.799
,0.001 37.0
aAlgorithm based only on clinical variables.
bAlgorithm for best fit model generated by linear stepwise regression using both clinical and genetic variables.
doi:10.1371/journal.pone.0037844.t002
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It is very difficult for clinicians to predict the accurate COA
dose and they depend totally on the traditional physical
parameters like sex, weight, height, and age to decide the dose
in advancing the therapy. Many evidences of role of genetic
markers, influencing warfarin dosage, were shown by different
investigators in last few years [13,14,30]. Genotyping of patients
having VKORC1, CYP2C9 and CYP4F2 variant alleles has been
shown to decrease the risk of over-anticoagulation in comparison
to a fixed initial dose approach [31,32]. Distribution of VKORC1-
1639 A, CYP2C9*2 and CYP2C9*3 allele frequencies were found to
be different for Indians when compared with selected HapMap
populations [33]. The ground for population specific dosing
regimens, for patients on anticoagulation, is established by such
interethnic differences in allele frequencies. The VKORC1 21639
G.A polymorphism is present in the promoter region of the
coding sequence so it decreases the enzyme expression if present in
homozygous recessive state. The CYP2C9*2 and *3 polymor-
phisms are located in exonic region and they decrease the drug
clearance as evidenced by Rettie et al. [34] in 1994. We have
found only two patients with CYP2C9*2*3 genotype and they
required comparatively lower drug doses than those with
CYP2C9*1*1, *1*2 or *1*3 genotypes. Since the CYP2C9 enzyme
is involved in metabolism of COAs, decrease in their activity will
result in lower maintenance drug doses to achieve therapeutic
INR.
To prevent the phenotypic extremities of COA treatment, many
attempts have been made to develop pharmacogenetics guided
dosing regimens for warfarin [12,17,21,28,29,35]. The Clinical
Pharmacogenetics Implimentation Consortium (CPIC) has pub-
lished guidelines for the use of pharmacogenomic tests in warfarin
dosing (J A Johnson et al.). Many studies have proposed warfarin
dosing algorithms based on both genetic and non-genetic factors
Table 3. Comparision of performance of new algorithms with clinical data.
Performance measures Multiple regression algorithm Stepwise regression algorithm Clinical data
Sensitivity 76% 71% 51%
Specificity 64% 58% 49%
Rate of overestimation 22% 23% 27%
Rate of underestimation 15% 13% 23%
Accuracy in all cases 63% 64% 50%
Accuracy in drug sensitive cases 60% 59% 51%
Accuracy in drug resistant cases 72% 71% 49%
Cronbach’s Alpha 0.56 0.49 0.11
doi:10.1371/journal.pone.0037844.t003
Table 4. Mean weekly doses and mean absolute errors according to different algorithms.
Algorithm
Mean Weekly Dose
(Standard Deviation, 95% CI
Confidence Interval)
Mean Absolute Error
(Standard Deviation, 95% CI Confidence Interval)
New Algorithm
a 21.26 (4.82, 20.30–22.21) 0.06 (7.62,21.57–1.45)
Schie et al. [27]
b 23.56 (4.67, 22.63–24.49) 2.25 (7.86, 0.69–3.81)
Schie et al. [27]
c 17.84 (3.11, 17.22–18.45) 23.48 (7.36,24.9422 2.02)
Anderson et al. [7] 40.48 (9.55, 38.58–42.37) 19.16 (9.45, 17.28–21.04)
Gage et al.[35] 37.16 (6.98, 35.78–38.54) 15.84 (9.10, 14.03–17.65)
Sconce et al. [17] 37.01 (9.56, 35.11–38.90) 15.70 (9.89, 13.74–17.66)
Wadelius et al. [21] 53.70 (11.64, 51.39–56.01) 32.39 (11.37, 30.13–34.65)
Oner Ozgon et al. [28] 27.16 (1.19, 26.92–27.40) 5.84 (7.96, 4.26–7.42)
Wen et al. [29] 27.87 (4.94, 26.89–28.85) 6.56 (7.23, 5.13–7.99)
Carlquist et al. [43] 27.40 (19.91, -11.35– 23.45) 228.72 (21.08,232.9– 224.54)
Zhu et al. [44] 37.56 (8.87, 35.8–39.32) 16.25 (8.63, 14.54–17.96)
IWPC
c [36] 37.40 (8.46, 35.7–39.08) 16.09 (8.56, 14.39–17.79)
Miao et al. [45] 37.47 (12.08, 35.07–39.87) 16.16 (11.11, 13.96–18.36)
Ohno et al. [46] 43.64 (11.43, 41.37–45.90) 22.33 (10.48, 20.25–24.41)
Therapeutic Dose
d 21.31 (8.35, 19.65–22.97)
aAlgorithm based on multiple regression.
bAcenocoumarol dosing algorithm,
cPhenprocoumon dosing algorithm.
cIWPC: International Warfarin Pharmacogenetic Consortium.
dOur cohort.
doi:10.1371/journal.pone.0037844.t004
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have different model fitness as evidenced from the R
2 values
ranging from 34 to 63. There are only a few reports about
pharmacogenetic dosing algorithms of acenocoumarol and phen-
procoumon. In a recent large European cohort study, acenocou-
marol and phenprocoumon algorithms were found to explain
59.4% and 49.0% variations in dose requirements respectively
[27]. In the present study, we have generated a new dosing
algorithm which is useful in predicting acenocoumarol doses in the
Indian population. We have been able to show that 41.4% of the
variability in daily maintenance acenocoumarol doses was
explained by our pharmacogenetic dosing model based on age,
gender, height, weight, BSA, smoking status, indication for cardiac
valve replacement surgery, VKORC1 -1639 G.A, CYP4F2 1347
G.A, CYP2C9*2, *3 and GGCX 12970 C.G polymorphisms.
The dosage data generated by our pharmacogenetic algorithm
displayed similar skewness as by the therapeutic maintenance
dosage data. van Schie et al. [27] acenocoumarol dosing algorithm
was most identical to our algorithm in terms of mean weekly dose
values. The mean weekly dosage and associated standard
deviation for the new algorithm and the van Schie et al. [27]
acenocoumarol dosing algorithm is close to that obtained in case
of therapeutic data (Table 4). The new algorithm was found to be
least erroneous as the MAE was minimum in its case. van Schie
et al. [27] acenocoumarol dosing algorithm was very close to our
algorithm in this aspect also. Out of other 13 algorithms, 12 were
derived from warfarin treated patients and 1 was derived from
phenprocoumon treated patients. These algorithms show moder-
ate to higher differences in mean weekly dose and MAE values
from the therapeutic dosage data. This observation suggested drug
specificity of dosing algorithms and advocated our approach. A
single study from south India had used genetic and clinical
parameters to develop a pharmacogenetics based dosing algorithm
for warfarin and it was found to be more useful in predicting the
stabilising drug doses [37]. We have not used their algorithm to
predict drug doses for our patient cohort as it uses complex
information of vitamin K intake and additional polymorphisms in
VKORC1 gene. Our main aim was to target most relevant markers
to predict drug dose and keep the algorithm simple. Due to the
difference in the type of drug (acenocoumarol in place of warfarin),
genetic differences [33,38] and dietary pattern of north Indians
and south Indians, there is a need to derive a dosing regimen for
acenocoumarol which is widely used in India.
The new algorithm was compared with the clinical data for
different performance measures. It was significantly sensitive (76%
vs 51%) than clinical data. The specificity was also increased if new
algorithm was used to predict the dose (64% vs 49%). There was
decrease in rate of over- and underestimation when new algorithm
was compared with clinical data. Moderate increase in accuracy
was observed for new algorithm in acenocoumarol sensitive cases
and it was significant in acenocoumarol resistant cases (72% vs
49%). The overall accuracy was also higher for new algorithm
than clinical data (63% vs 50%). The higher value of the
Cronbach’s Alpha constant in case of our algorithm as compared
with the clinical data (0.56 vs 0.11) proves again the closer
proximity of our algorithm with the therapeutic dosing.
We have found a strong association of acenocoumarol sensitivity
with the heterozygocity and homozygocity for the VKORC1-1639
G.A change. The presence of GA or AA genotype results in very
high risk of overdosing. In this condition the drug target enzyme is
expressed in lower amounts so lower drug doses can achieve
therapeutic INR range in early stage of treatment. Pavani et al.
[37] have also reported the high risk of warfarin sensitivity for
VKORC1-1639 G.A polymorphism. We have also looked for
association of other genotypes in drug sensitive, resistant and
intermediate dose groups but could not get any significant one. So
we can say that VKORC121639 G.A polymorphism is the key
player in drug sensitivity. We have observed presence of CYP4F2
1347 G.A polymorphism in the linear stepwise dosing algorithm
but it was not found to be associated with any of the dose groups.
This may be due to the fact that the linear stepwise regression
generates a best fit model for a scalar outcome. This analysis uses
both categorical as well as scalar variables as inputs. In contrast,
the binary logistic regression used for associating polymorphisms
with drug dose groups uses only categorical variables as inputs and
it calculates the risk as odds ratios. In other words, we can say that
VKORC1, CYP4F2, weight and gender explain 37% of variation
in acenocoumarol dosage requirements. The R
2 values of 41.4%
and 37% in respective cases of linear stepwise regression and
multiple regression algorithms suggest that VKORC1 and
CYP4F2 are major contributors in acenocoumarol dosage
variability. The contributions of VKORC1and CYP4F2 geno-
types in overall predictive power of dosing algorithm are 21% and
3.7% respectively. There is only ,4% increase in R
2 value by
including the other genetic factors like CYP2C9 and GGCX and
other non-genetic factors in multiple regression modelling.
Cardiac valve replacement surgery phenotypes (double/mitral/
aortic valve replacement) have ,1.5% contribution in explaining
the variability of dose requirements. This is reflected by the fact
that excluding these variables from multiple regression modelling
Table 5. Association between acenocoumarol sensitive/resistant/intermediate dose groups and polymorphisms.
Polymorphism
Acenocoumarol
sensitive vs other groups,
Odds ratio (95% Confidence Interval)
Acenocoumarol
resistant vs other groups,
Odds ratio (95% Confidence Interval)
Acenocoumarol intermediate
dose vs other groups,
Odds ratio (95%
Confidence Interval)
VKORC1 21639 GA+AA 4.42 (2.44–7.99
#) 0.17 (0.08–0.37) 0.91 (0.50–1.66)
CYP4F2 1347 GA 0.87 (0.47–1.63) 1.58 (0.82–3.03) 0.74 (0.40–1.38)
CYP4F2 1347 AA 1.25 (0.57–2.74) 1.52 (0.67–3.46) 0.51 (0.22–1.20)
CYP2C9*1*2 1.52 (0.63–3.64) 0.68 (0.26–1.80) 0.92 (0.36–2.35)
CYP2C9*1*3 1.93 (0.97–3.87) 0.62 (0.28–1.34) 0.77 (0.36–1.65)
GGCX 12970 CG 0.69 (0.18–2.66) 0.75 (0.19–2.89) 1.84 (0.54–6.26)
GGCX 12970 GG 0.00 (0.00–0.00) 1.98 (0.12–32.21) 2.21 (0.14–35.90)
#P-value is statistically significant.
doi:10.1371/journal.pone.0037844.t005
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phisms gives an algorithm with R
2 value of 40%. This also reflects
that CYP2C9*2, *3 and GGCX 12970 C.G polymorphisms
explain about 3% of variability in the acenocoumarol dosage
requirements.
The low frequencies of CYP2C9*2, *3 and GGCX 12970 C.G
polymorphisms in north Indian population explain the lower
contribution of these markers in variability in dosage require-
ments. Also, the CYP2C9*2 and *3 alleles are less frequent in the
derivation cohort so their contribution is small in the algorithm.
This is a limitation of our study as there may be some bias in
patient selection for the two cohorts. Moreover, Loebstein et al.
[39] reported that an Arg36Tyr polymorphism VKORC1 was
responsible for higher dose requirement in warfarin resistant
patients and was significantly associated with higher drug dose
requirement. As we have not analysed this polymorphism in our
patient group, it is possible that this or some other polymorphisms
might also contribute to some extent for acenocoumarol resistance.
Conclusion
The multiple regression algorithm can be used for a more
accurate prediction of acenocoumarol doses. It explains 41.4%
variability in acenocoumarol dosage requirements. The linear
stepwise algorithm uses genotyping of only two polymorphisms
and it can be used for better cost to benefit ratio as its results are
comparable with the more complex multiple regression algo-
rithms. Polymorphisms in VKORC1 and CYP4F2 came out to be
the principal genetic determinants explaining 37% acenocoumarol
dosage variability. The less frequent CYP2C9*2, *3 and GGCX
12970 C.G polymorphisms in Indian population do determine
the dosage variability but to an extent of ,3% only. In
comparison to other dosing models, which are mostly based on
warfarin, our drug specific algorithms show more accurate
acenocoumarol dosage prediction.
Future perspective
Development of new oral anticoagulants like Dabigatran (direct
thrombin inhibitor) and Rivaroxaban (direct factor Xa inhibitor)
have sparked a new hope of overcoming the risk factors associated
with vitamin K antagonists. These new drugs may replace the
traditional oral anticoagulants in future.
However, till these new drugs are widely used, there is a need to
replicate this work in a larger sample size as well as in various
regions and ethnic groups of India before introduction in routine
clinical practice. Improved therapy outcomes based on such
studies will allow successful application of individualised dosing in
clinical setting.
Methods
Ethics Statement
The study protocol was approved by the institutional ethical
committee of Sanjay Gandhi Post Graduate Institute of Medical
Sciences (SGPGIMS). The authors followed the norms of World’s
Association Declaration of Helsinki. All the participants gave
written informed consent to participate in the study.
Patients
The present study was carried out on the DNA samples of
patients who had undergone surgery for aortic/mitral/double
valve replacement and were being followed-up for regular PT-
INR (Prothrombin Time-International Normalized Ratio) testing.
The PT-INR testing was done every 2 weeks for each patient. A
total of 7586 patients on COA therapy were screened and of
which 225 patients of northern Indian origin were recruited from
the outpatient department of Department of Cardiovascular and
Thoracic Surgery, Sanjay Gandhi Post Graduate Institute of
Medical Sciences and Department of Thoracic & Cardio-Vascular
Surgery, Chhatrapati Shahuji Maharaj Medical University,
Lucknow, India. The patient sample collection was done during
a period of about one and half year from March 2010 to August
2011. We have divided the patients into two cohorts, namely
derivation cohort of 125 patients and validation cohort of 100
patients. The selection of patients for derivation and validation
cohorts was done on a random basis. All these subjects were taking
maintenance dosage of acenocoumarol to achieve the INR in a
therapeutic range (between 2.0 to 3.5) for at least 3 consecutive
months. Patients aging less than 18 years or those suffering from
diabetes, liver disease, chronic diarrheal conditions or malabsorp-
tion were excluded from the study. Patients were given dietary
advice and food charts were prepared in order to avoid any
interference with acenocoumarol pharmacokinetics and pharma-
codynamics. Patients with interfering drug administration and
showing non-compliance and were excluded from the study.
Clinical data like age, body weight, height, gender, smoking habits,
indication for acenocoumarol therapy, average maintenance dose
and ethnicity were recorded. The average maintenance dose was
calculated as mean of the dose values during the 3 month period
when last two consecutive stable INR values were documented.
The north Indian ethnicity of patients was decided according to
their place of residence in the last three generations, food habits
and mother tongue (Hindi or related languages).
Genotyping
Blood samples were collected once in vacutainer vials coated
with ethylenediaminetetraacetic acid along with the samples taken
up for regular PT-INR tests. Standard salting-out method was
used to isolate genomic DNA from blood samples. DNA was
checked both for quantity as well as quality by gel electrophoresis
and spectrophotometry using the NanoDrop Analyzer (ND-1000)
spectrophotometer (NanoDrop Technologies, Wilmington, DE,
USA). The ratio of absorbance of DNA at 260 and 280unm were
between 1.7 and 1.9. The checked DNA was stored at 240uC.
The genotyping for VKORC1 -1639 G.A, CYP4F2 1347 G.A,
CYP2C9*2, *3 and GGCX 12970 C.G polymorphisms was done
by polymerase chain reaction and restriction fragment length
polymorphism (PCR–RFLP) [17,40–42]. Negative (genomic DNA
absent) and positive (known heterozygote) controls were used in
each PCR reaction. Genotyping was repeated in ,10% samples
by different lab members to check for genotyping errors and 100%
concordance was obtained. For the GGCX 12970 C.G polymor-
phism, Taqman probe-based genotyping was also performed by
using the ABI prism 7900 using SNP discrimination assays
designed by Applied Biosystems (ABI) (Applied Biosystems, Foster
City, CA, USA).
Statistical analyses
SPSS version 17.0 software (SPSS Japan, Tokyo, Japan) was
used to perform all the statistical analyses. Descriptive statistics was
used to calculate the patient characteristics. The minor allele
frequencies were calculated by counting the total number of alleles
for a particular SNP in all the patients and then dividing the allele
with low prevalence by the allele with higher prevalence and
expressed as percentage. The derivation cohort was used to
generate the pharmacogenetic model which was used to predict
the drug dosage in the validation cohort. The parameters used in
multiple regression for deriving the pharmacogenetic model were
age, sex, height, weight, body surface area (BSA), smoking status,
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G.A, CYP4F2 1347 G.A, CYP2C9*2, *3 and GGCX 12970 C.G
polymorphisms. A simpler pharmacogenetic model was also
developed by linear stepwise regression using the above said
variables. The genotype data was entered as 0 for absence and 1
for presence. We have not used complex dietary information of
vitamin K uptake because it was too difficult to obtain that in
clinical setting. Further, the patients were given dietary advice in
form of charts and any noncompliance in this regard was treated
as exclusion criteria. Apart from these pharmacogenetic algo-
rithms comprising of both genetic as well as clinical factors, we
have also generated an equation based only on clinical factors.
This was done by putting all except the genetic factors in linear
stepwise regression. We have extracted eleven algorithms through
literature search which use similar parameters for dosage
prediction. These algorithms were used to predict the doses based
on the patient profile in the validation cohort of our study. The
dosage predicted by our pharmacogenetic model was compared
with the therapeutic dosage and with those predicted by the twelve
algorithms. Of these 12 algorithms, 11 have been derived from
patient cohorts using warfarin for anticoagulation therapy. One
algorithm used patients on acenocoumarol treatment for deriving
pharmacogenetic dosing algorithm. For these comparisons, we
have computed the mean values of the dosage along with standard
deviation (SD) and 95% confidence interval (CI) values for each
algorithm. Comparison of the mean absolute error (MAE) of each
algorithm was used to evaluate the performance of each algorithm.
The absolute error values were calculated by deducting the actual
dose from the predicted dose and their means were defined as
MAE. The MAE values were calculated along with the SD and
95% CI values.
We have used SPSS software to make 3 quartiles of therapeutic
drug doses of all the patients. Patients on a maintenance dose of
#17.0 and $24.5 mg/week were considered acenocoumarol
sensitive and resistant respectively while the patients in the range
of 17.0-24.5 mg/week were assumed to be in intermediate range.
As a measure of association, odds ratio values for different
genotypes were calculated in both drug sensitive and drug resistant
groups. The performance of our pharmacogenetic algorithms was
compared with that of clinical algorithm in terms of sensitivity,
specificity, rate of over and underestimation, accuracy and
relatedness as a group. All these parameters were obtained by
calculations by Fisher’s exact test.
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